(Q35603537)

9 August 2017

title

Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. (English)

1 reference

9 August 2017

T A Williams

1

1 reference

9 August 2017

C P Blyth

series ordinal

2

1 reference

9 August 2017

publication date

16 September 2011

1 reference

9 August 2017

1 reference

9 August 2017

volume

25

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1617-1621

1 reference

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

Ranibizumab for neovascular age-related macular degeneration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3234468

Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration: clinically relevant natural history information in larger lesions with good vision from the Verteporfin in Photodynamic Therapy (VIP) Trial: VIP Repo

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21921947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21921947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21921947

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/EYE.2011.224

1 reference

9 August 2017

1 reference

9 August 2017

1 reference